Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases

Rocha, Henrique Carvalho; Vilela, Eduardo García

doi:10.1016/j.gastrohep.2021.03.011

Cited by 6 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 27 , 28 There were no patient deaths in the PSC subgroup despite the high cumulative rate of LT. Progression to transplantation was related to the length of time from AILD diagnosis on account of development of complications; a recent study highlighted an accelerated risk in patients with PHT, 68% of which consisted of PSC patients with UC, 29 a finding comparable to our cohort. Liver-related deaths were mostly from complications of decompensated cirrhosis and sepsis.…”

Section: Discussionsupporting

confidence: 82%

Biliary disease progression in childhood onset autoimmune liver disease: A 30-year follow-up into adulthood

Warner,

Rajanayagam,

Russell

et al. 2024

JHEP Reports

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 82%

Biliary disease progression in childhood onset autoimmune liver disease: A 30-year follow-up into adulthood

Warner,

Rajanayagam,

Russell

et al. 2024

JHEP Reports

View full text Add to dashboard Cite

“…The recurrence of ulcerative colitis is 30% and Crohn's disease is 80% in patients with PSC. 38 Patients with PSC associated with ulcerative colitis had a higher risk of developing colorectal cancer compared to patients with ulcerative colitis alone. 39 The risk of de novo IBD is also much higher in transplant patients who die of PSC or autoimmune hepatitis.…”

Section: Prognosis Of Liver Disease Associated With Ibdmentioning

confidence: 95%

Liver Disease Associated with Inflammatory Bowel Disease

Kurniawan,

Budiman

2024

InaJGHE

View full text Add to dashboard Cite

Inflammatory Bowel Disease (IBD) is a chronic condition characterized by persistent inflammation of the gastrointestinal tract, comprising ulcerative colitis (UC) and Crohn’s disease (CD). While the current global incidence of IBD exceeds 0.3% in Western nations, Indonesia reports a comparatively lower prevalence however with projections indicate a potential rise in incidence from 2020 to 2050. Hepatobiliary manifestation is one of the most common extraintestinal manifestations of IBD. Some of the liver disease associated with IBD had similar background immune response, inflammatory reaction, similar risk factor, or due to the treatment of IBD. Primary sclerosing cholangitis (PSC) has close association with IBD and both affect the prognostic and disease progression of each other. Non-alcoholic fatty liver disease (NAFLD) shares common metabolic risk factors. Several drugs used as the treatment of IBD might cause hepatic injury especially due to the long treatment duration of IBD. Hepatitis B reactivation is another concerning event found after prolonged used of immunosuppressive drugs of IBD. Therefore, close monitoring of liver function test periodically is a mandatory test to screen liver disease in IBD patients. Keyword: Inflammatory bowel disease, liver disease, autoimmune hepatitis, drug-induced liver injury

show abstract

“…опубликовали данные динамического исследова-ния 54 пациентов с аутоиммунными заболеваниями печени и ВЗК, большинство из которых -пациенты с ЯК и ПСХ (64,5%). Ретроспективный анализ, проведенный исследователями, продемонстрировал ассоциацию предшествующего диагноза АИГ и дебюта ВЗК de novo после трансплантации печени у этих больных (ОШ 7,1, 95% ДИ 1,2-42,4; p=0,012) [72]. В литературе есть сведения о более частом синдроме перекреста АИГ и ПСХ у пациентов с ВЗК, который чаще наблюдается у пациентов с ЯК, чем у пациентов с БК [60].…”

Section: внекишечные проявленияunclassified

Inflammatory bowel diseases: Transformation of representations. A review

Maev,

Bakulin,

Skalinskaya

et al. 2023

Terapevticheskii arkhiv

View full text Add to dashboard Cite

The global burden of inflammatory bowel disease (IBD) is currently significant and continues to grow due to the increasing prevalence of ulcerative colitis (UC) and Crohn's disease (CD), the increasing costs of diagnosis and treatment, and the high level of disability in patients with this disease. Categories, which leads to the search for risk factors and predictors of aggressive course and extraintestinal manifestations. According to the latest data, the prevalence of UC in Russia is 16.6 per 100 000 population, the annual registered increase is 11.3%; the prevalence of CD is 5.6 per 100 000 population, and the increase is 13.7%. In the Russian population of patients with IBD, the average age of disease onset is 35.3 years for UC and 31.2 years for CD. Moreover, in 89.3% of patients with UC, it took at least 2 years to verify the diagnosis, and in CD, within 2 years from the onset of clinical symptoms, the diagnosis was established in only 72.6% of patients. One of the dominant characteristics of IBD is its multisystem nature, which leads to the development of extraintestinal manifestations (ECM), which can be observed in 50–60% of patients, while up to 25% of patients with IBD have several EMC and the most common variants are joint lesions. A higher frequency of extraintestinal manifestations is observed in CD (up to 45% of patients), in female patients, in smokers and with a longer duration of the disease. To predict clinical remission, the level of fecal calprotectin and CRP, the need for glucocorticosteroids are important, to predict endoscopic remission – the level of fecal calprotectin, and to predict histological remission, an endoscopic Schroeder index value of ≤1 is important. The absolute risk of developing colorectal cancer in IBD remains relatively low, ranging from 1.1 to 5.4% after 20 years of disease. The main risk factors for IBD are total intestinal damage, high inflammatory activity, the stricturing phenotype of CD and the presence of primary sclerosing cholangitis.

show abstract

Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases

Cited by 6 publications

References 38 publications

Biliary disease progression in childhood onset autoimmune liver disease: A 30-year follow-up into adulthood

Biliary disease progression in childhood onset autoimmune liver disease: A 30-year follow-up into adulthood

Liver Disease Associated with Inflammatory Bowel Disease

Inflammatory bowel diseases: Transformation of representations. A review

Contact Info

Product

Resources

About